{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:13:25Z","timestamp":1787505205994,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.repc.2019.03.005","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T08:15:28Z","timestamp":1566461728000},"page":"531-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["CODAP: um consenso multidisciplinar sobre a defini\u00e7\u00e3o, diagn\u00f3stico e tratamento da dislipidemia aterog\u00e9nica em Portugal"],"prefix":"10.1016","volume":"38","author":[{"given":"Alberto","family":"Mello e Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Sequeira Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Teixeira Ver\u00edssimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Marques da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2019.03.005_bib0255","unstructured":"OECD. Health at a Glance 2017: OECD Indicators, 2017; OECD Publishing, Paris. doi: doi.org\/10.1787\/health_glance\u20102017\u2010en."},{"key":"10.1016\/j.repc.2019.03.005_bib0260","unstructured":"Instituto Nacional de Estat\u00edstica. Causas de morte 2016. 2018. Dispon\u00edvel em: www.ine.pt."},{"issue":"1 SUPPL","key":"10.1016\/j.repc.2019.03.005_bib0265","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/j.amjcard.2009.10.007","article-title":"Cardiovascular Disease Risk Factors: Epidemiology and Risk Assessment","volume":"105","author":"Dahl\u00f6f","year":"2010","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2019.03.005_bib0270","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2125.2012.04219.x","article-title":"Cardiovascular risk","volume":"74","author":"Payne","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.repc.2019.03.005_bib0275","first-page":"99","article-title":"Dislipidemia aterog\u00e9nica","volume":"38","author":"Mello e Silva","year":"2015","journal-title":"Rev Factores Risco."},{"key":"10.1016\/j.repc.2019.03.005_bib0280","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.repc.2019.03.005_bib0285","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/db16-0046","article-title":"Pharmacological targeting of the atherogenic dyslipidemia complex: The next frontier in CVD prevention beyond lowering LDL cholesterol","volume":"65","author":"Xiao","year":"2016","journal-title":"Diabetes."},{"key":"10.1016\/j.repc.2019.03.005_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-017-0591-5","article-title":"Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross\u2010sectional observational study","volume":"17","author":"Halcox","year":"2017","journal-title":"BMC Cardiovasc Disord."},{"key":"10.1016\/j.repc.2019.03.005_bib0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","article-title":"Persistent lipid abnormalities in statin\u2010treated patients and predictors of LDL\u2010cholesterol goal achievement in clinical practice in Europe and Canada","volume":"19","author":"Gitt","year":"2012","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.repc.2019.03.005_bib0300","first-page":"47","article-title":"Anomalias lip\u00eddicas persistentes em doentes tratados com estatinas: Resultados portugueses do estudo internacional de dislipidemia (DYSIS)","volume":"30","author":"Marques Da Silva","year":"2011","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2019.03.005_bib0305","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid\u2010lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.repc.2019.03.005_bib0310","first-page":"109","article-title":"The RAND \/UCLA Appropriateness Method User\u2019 s Manual","author":"Fitch","year":"2001","journal-title":"Transformation."},{"key":"10.1016\/j.repc.2019.03.005_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2014-006682","article-title":"Standardised method for reporting exercise programmes: Protocol for a modified Delphi study","volume":"4","author":"Slade","year":"2014","journal-title":"BMJ Open."},{"key":"10.1016\/j.repc.2019.03.005_bib0320","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.recesp.2013.06.014","article-title":"Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterog\u00e9nica","volume":"67","author":"Mill\u00e1n N\u00fa\u00f1ez-Cort\u00e9s","year":"2014","journal-title":"Rev Espa\u00f1ola Cardiol."},{"key":"10.1016\/j.repc.2019.03.005_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1567-5688(15)30001-5","article-title":"A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate\u2010statin combination therapy","volume":"19","author":"Aguiar","year":"2015","journal-title":"Atheroscler Suppl."},{"key":"10.1016\/j.repc.2019.03.005_bib0330","first-page":"168","article-title":"Adaptaci\u00f3n espa\u00f1ola de un Consenso Europeo de Expertos","volume":"29","year":"2017","journal-title":"Clin e Investig en Arterioscler."},{"key":"10.1016\/j.repc.2019.03.005_bib0335","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","article-title":"Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia","volume":"18","author":"Ferrari","year":"2016","journal-title":"Eur Hear Journal, Suppl."},{"key":"10.1016\/j.repc.2019.03.005_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2017.05.059","article-title":"Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment","author":"Ponte-Negretti","year":"2017","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.repc.2019.03.005_bib0345","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the Europea","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis."},{"issue":"10 SUPPL.","key":"10.1016\/j.repc.2019.03.005_bib0350","first-page":"319","article-title":"The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2019.03.005_bib0355","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"issue":"SUPP.1","key":"10.1016\/j.repc.2019.03.005_bib0360","first-page":"3","article-title":"Dianas terap\u00e9uticas en el tratamiento de las dislipemias: Colesterol no unido a lipoprote\u00ednas de alta densidad y colesterol unido a lipoprote\u00ednas de alta densidad","volume":"26","author":"Brea Hernando","year":"2014","journal-title":"Clin e Investig en Arterioscler."},{"key":"10.1016\/j.repc.2019.03.005_bib0365","first-page":"265","article-title":"La aut\u00e9ntica dimensi\u00f3n del colesterol\u2010no\u2010HDL: colesterol aterog\u00e9nico","volume":"28","author":"Mill\u00e1n","year":"2016","journal-title":"Clin e Investig en Arterioscler."},{"key":"10.1016\/j.repc.2019.03.005_bib0370","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11883-011-0224-x","article-title":"The role of non\u2010HDL cholesterol in risk stratification for coronary artery disease","volume":"14","author":"Rana","year":"2012","journal-title":"Curr Atheroscler Rep."},{"key":"10.1016\/j.repc.2019.03.005_bib0375","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.repc.2019.03.005_bib0380","unstructured":"Expert Dyslipidemia Panel of the International Atherosclerosis Society. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia \u2010 Full report. J Clin Lipidol. 2014;8(1):29\u201060."},{"issue":"Supplement 2","key":"10.1016\/j.repc.2019.03.005_bib0385","first-page":"1","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract [Internet]."},{"key":"10.1016\/j.repc.2019.03.005_bib0390","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association Recommendations for Patient\u2010Centered Management of Dyslipidemia: Part 1 \u2010 Executive Summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol [Internet]."},{"key":"10.1016\/j.repc.2019.03.005_bib0395","unstructured":"National Clinical Guideline Centre (UK). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Institute for Health and Clinical Excellence: Guidance. London: National Institute for Health and Care Excellence (UK); 2014 Jul"},{"key":"10.1016\/j.repc.2019.03.005_bib0400","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.atherosclerosissup.2018.04.001","article-title":"Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC\/EAS dyslipidaemia guidelines \u2013 Full report","volume":"31","author":"Marques da Silva","year":"2018","journal-title":"Atheroscler Suppl."},{"key":"10.1016\/j.repc.2019.03.005_bib0405","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol [Internet]."},{"key":"10.1016\/j.repc.2019.03.005_bib0410","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non\u2010fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2019.03.005_bib0415","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.03.005_bib0420","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/eurheartj\/ehx659","article-title":"Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy According to European Society of Cardiology\/European Atherosclerosis Society guidelines: A contemporary population\u2010based study","volume":"39","author":"Madsen","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2019.03.005_bib0425","unstructured":"ClinicalTrials.gov. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4g\/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE\u2010IT). NCT01492361. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01492361. Acesso 14\/03\/2018."},{"key":"10.1016\/j.repc.2019.03.005_bib0430","unstructured":"ClinicalTrials.gov. Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH). NCT02104817. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02104817. Acesso 14\/03\/ 2018."},{"key":"10.1016\/j.repc.2019.03.005_bib0435","unstructured":"ClinicalTrials.gov. Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT). NCT03071692. https:\/\/clinicaltrials.gov\/show\/NCT03071692. Acesso 14\/03\/2018."},{"key":"10.1016\/j.repc.2019.03.005_bib0440","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"lancet Diabetes Endocrinol"},{"key":"10.1016\/j.repc.2019.03.005_bib0445","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jacl.2013.08.001","article-title":"High\u2010density lipoproteins: A consensus statement from the National Lipid Association","volume":"7","author":"Toth","year":"2013","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.repc.2019.03.005_bib0450","doi-asserted-by":"crossref","unstructured":"The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362(17):1563\u201074.","DOI":"10.1056\/NEJMoa1001282"},{"key":"10.1016\/j.repc.2019.03.005_bib0455","doi-asserted-by":"crossref","unstructured":"The FIELD study investigators. Effects of long\u2010term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366(9500):1849\u201061.","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"10.1016\/j.repc.2019.03.005_bib0460","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1517\/14656566.2013.850075","article-title":"Summarizing the FIELD study: lessons from a \u2018negative\u201d trial.\u2019","volume":"14","author":"Tsimihodimos","year":"2013","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.repc.2019.03.005_bib0465","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2165\/11208090-000000000-00000","article-title":"Fenofibrate: A review of its use in dyslipidaemia","volume":"71","author":"McKeage","year":"2011","journal-title":"Drugs."},{"key":"10.1016\/j.repc.2019.03.005_bib0470","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11886-011-0237-7","article-title":"Do persons with diabetes benefit from combination statin and fibrate therapy?","volume":"14","author":"Rosenblit","year":"2012","journal-title":"Curr Cardiol Rep."},{"key":"10.1016\/j.repc.2019.03.005_bib0475","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/11207690-000000000-00000","article-title":"A review of its lipid\u2010modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus","volume":"11","author":"Keating","year":"2011","journal-title":"Am J Cardiovasc Drugs."},{"key":"10.1016\/j.repc.2019.03.005_bib0480","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD\u2010Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin Lipidol."},{"key":"10.1016\/j.repc.2019.03.005_bib0485","doi-asserted-by":"crossref","unstructured":"The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods. Am J Cardiol. 2007; 99.(12).","DOI":"10.1016\/j.amjcard.2007.03.003"},{"issue":"4a","key":"10.1016\/j.repc.2019.03.005_bib0490","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","article-title":"Association of fenofibrate therapy with long\u2010term cardiovascular risk in statin\u2010treated patients with type 2 diabetes","volume":"2","author":"Elam","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.repc.2019.03.005_bib0495","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: A systematic review and meta\u2010analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.repc.2019.03.005_bib0500","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National lipid association recommendations for patient\u2010centered management of dyslipidemia: Part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol."}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255118306358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255118306358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:48Z","timestamp":1760108868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255118306358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0870255118306358"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2019.03.005","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CODAP: um consenso multidisciplinar sobre a defini\u00e7\u00e3o, diagn\u00f3stico e tratamento da dislipidemia aterog\u00e9nica em Portugal","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2019.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}